<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAE7F8F7-1B15-47CA-844D-044010E02914"><gtr:id>DAE7F8F7-1B15-47CA-844D-044010E02914</gtr:id><gtr:name>University of Hasselt</gtr:name><gtr:address><gtr:line1>Campus Diepenbeek</gtr:line1><gtr:line2>Agoralaan Gebouw D</gtr:line2><gtr:line3>BE 3590</gtr:line3><gtr:line4>Diepenbeek</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DC3CB67-AB5C-4DC1-B3D5-4390FC4078E3"><gtr:id>9DC3CB67-AB5C-4DC1-B3D5-4390FC4078E3</gtr:id><gtr:name>Joint United Nations Programme on HIV/AIDS (UNAIDS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B52D514-B601-466C-9D14-9692C202FC9A"><gtr:id>4B52D514-B601-466C-9D14-9692C202FC9A</gtr:id><gtr:name>European Monitoring Centre for Drugs and Drug Addiction</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B96272D9-51DB-4698-AC93-6F9823C379D9"><gtr:id>B96272D9-51DB-4698-AC93-6F9823C379D9</gtr:id><gtr:name>University of Manitoba</gtr:name><gtr:address><gtr:line1>University of Manitoba</gtr:line1><gtr:line4>Winnipeg</gtr:line4><gtr:line5>Manitoba</gtr:line5><gtr:postCode>R3T 2N2</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3C3A3D9C-2AAF-42B6-ABEF-259677C4D8E4"><gtr:id>3C3A3D9C-2AAF-42B6-ABEF-259677C4D8E4</gtr:id><gtr:name>NHS National Services Scotland (NSS)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Public Health and Policy</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAE7F8F7-1B15-47CA-844D-044010E02914"><gtr:id>DAE7F8F7-1B15-47CA-844D-044010E02914</gtr:id><gtr:name>University of Hasselt</gtr:name><gtr:address><gtr:line1>Campus Diepenbeek</gtr:line1><gtr:line2>Agoralaan Gebouw D</gtr:line2><gtr:line3>BE 3590</gtr:line3><gtr:line4>Diepenbeek</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DC3CB67-AB5C-4DC1-B3D5-4390FC4078E3"><gtr:id>9DC3CB67-AB5C-4DC1-B3D5-4390FC4078E3</gtr:id><gtr:name>Joint United Nations Programme on HIV/AIDS (UNAIDS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3C3A3D9C-2AAF-42B6-ABEF-259677C4D8E4"><gtr:id>3C3A3D9C-2AAF-42B6-ABEF-259677C4D8E4</gtr:id><gtr:name>NHS National Services Scotland (NSS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B52D514-B601-466C-9D14-9692C202FC9A"><gtr:id>4B52D514-B601-466C-9D14-9692C202FC9A</gtr:id><gtr:name>European Monitoring Centre for Drugs and Drug Addiction</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B96272D9-51DB-4698-AC93-6F9823C379D9"><gtr:id>B96272D9-51DB-4698-AC93-6F9823C379D9</gtr:id><gtr:name>University of Manitoba</gtr:name><gtr:address><gtr:line1>University of Manitoba</gtr:line1><gtr:line4>Winnipeg</gtr:line4><gtr:line5>Manitoba</gtr:line5><gtr:postCode>R3T 2N2</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9BE4E56D-F29C-4E33-8531-2E38A920C12A"><gtr:id>9BE4E56D-F29C-4E33-8531-2E38A920C12A</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Vickerman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701627"><gtr:id>2018BB67-93AA-42C1-8E6F-502B6AEE8B6F</gtr:id><gtr:title>Modelling the determinants and implications of the disparate trends in HCV and HIV amongst injecting drug users</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701627</gtr:grantReference><gtr:abstractText>Hepatitis C (HCV) and HIV are viral infections that cause substantial morbidity and mortality amongst humans, with both infections being easily transmitted amongst injecting drug users when they share syringes. Reducing the ease with which they are propagated through injecting drug use is important for controlling their spread in most countries, with the main strategies for reducing transmission being the distribution of clean syringes, reducing their injecting frequency through supplying them with orally administered drug substitutes (frequently methadone), and other interventions seeking to reduce the frequency with which IDUs share syringes or inject. However, although there is evidence that these control strategies can reduce the rate of spread of HIV, there is little equivalent evidence for HCV. Indeed, this uncertainty and the fact that there is confusion over why certain populations of injecting drug users have much lower prevalences of HCV infection than others, has made it impossible for policy makers to produce clear guidelines on what coverage of specific control strategies is required to reduce the spread of these infections to a certain degree. This project plans to develop a mathematical model to simulate the time dependent trends in the prevalence of HCV and HIV infection of a number of injecting drug user populations experiencing different sizes of epidemic. The use of data from a number of sites will result in the model giving insights in to what aspects of the behaviour of injecting drug users was important for increasing the spread of the infections in certain settings, and so will identify what aspects of their behaviour could be focussed on to control their spread. The model will then be used to simulate the likely impact of different control strategies for reducing the spread of both infections amongst different populations of injecting drug users. Five control strategies will be simulated by the model, including the distribution of clean syringes, use of orally administered drug substitution therapy, educating injecting drug users to reduce risky behaviours, treating injecting drug users to cure their HCV infection, and providing treatment to delay the progression of HIV infection. The model projections will be used to help policy makers to produce targets for how much of a particular control strategy is needed to achieve a certain reduction in the spread of HIV and HCV infection in a particular population.</gtr:abstractText><gtr:technicalSummary>Hepatitis C (HCV) and HIV cause substantial morbidity and mortality, with both infections being easily transmitted through infected syringes. Reducing the transmission of HCV and HIV through injecting drug use is critical to the overall prevention of these infections in most countries, with the main prevention strategies being syringe distribution, methadone substitution therapy, and other interventions seeking to reduce syringe sharing or injecting frequency. However, although there is evidence that these interventions can reduce HIV transmission, there is little equivalent evidence for HCV, and considerable confusion over why certain IDU populations have much smaller epidemics than others, and why IDU populations with very similar HIV prevalence can have widely different HCV prevalences. These gaps in our understanding has made it impossible for policy makers to develop clear guidelines on the scale of activity required to achieve substantial impact, or on what mix of interventions may be optimal. This project plans to use longitudinal HCV and HIV epidemiological and behavioural data from a number of IDU populations experiencing different types of epidemic to develop, fit and validate a joint model of HIV and HCV transmission. The data synthesis from a number of sites will provide informative data to inform model selection, validation and reduce parameter uncertainty. In addition, the differences between the model parameterisations for different settings will give pointers to what aspects of IDU risk behaviour may be associated with increased transmission, and so be focussed on by interventions. The different model fits will then be used to project the likely impact of different intervention activities for reducing the joint the transmission of HIV and HCV amongst IDUs in different HIV/HCV epidemics and at different stages of these epidemics. Five interventions will be considered ( syringe distribution, substitution therapy, risk reduction through outreach information and education, HCV treatment, and HIV treatment), and coverage and activity targets will be estimated for attaining specified reductions in HCV or HIV transmission.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>332194</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS National Services Scotland (NSS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Health Protection Scotland</gtr:department><gtr:description>Collaboration with Health Protection Scotland</gtr:description><gtr:id>A5C80C56-F92E-4C1E-A383-F02CD1C5374B</gtr:id><gtr:impact>We are currently collaborating on trying to undertake a trial/study to evaluate HCV treatment as a prevention strategy in the field. We have also published a number of joint papers:

21145810 Martin Natasha K (2011) Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility., Journal of hepatology 54, 6, 1137-44
 
21236265 Martin Natasha K (2011) Mathematical modelling of hepatitis C treatment for injecting drug users., Journal of theoretical biology 274, 1, 58-66
 
21615585 Turner Katy M E (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence., Addiction 106, 11, 1978-88
 
21898506 Martin Natasha K (2011) The cost-effectiveness of HCV antiviral treatment for injecting drug user populations., Hepatology (Baltimore, Md.)</gtr:impact><gtr:outcomeId>iU2t8tYqaQc-1</gtr:outcomeId><gtr:partnerContribution>Provision of data for modelling and pooled analysis of the effect of OST and NSP on HCv incidence. Also contributed to formulation of research ideas and writing of papers</gtr:partnerContribution><gtr:piContribution>We have developed a model to estimate the impact of HCV treatment on the transmission of HCV in different settings. The model has recently been adapted to estimate the resulting cost-effectiveness of this strategy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Burnet Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Centre for Infection</gtr:department><gtr:description>Collaboration with Burnet Institute, Melbourne</gtr:description><gtr:id>9806800D-9BE4-4DB9-ACF6-2846E91BDE48</gtr:id><gtr:impact>I am joiontly supervising a PHD student that is using Bayesian MCMC techniques to estimate uinbiased estimates of HCV reinfection incidence and clearance from an International pooled dataset of cohort studies that done re-infection studies amongst IDUs. We have also published a number of papers from our collaboration and have other papers in review:

20650522 Degenhardt Louisa (Jul, 2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed., Lancet 376, 9737, 285-301 

Vickerman, Peter (2011) The more you look the more you find - Effects of hepatitis C virus testing interval on re-infection incidence and clearance: Implications for future vaccine study design, Journal of Infectious Diseases In press</gtr:impact><gtr:outcomeId>oDQXQt6jLq9-1</gtr:outcomeId><gtr:partnerContribution>They have provided data for modelling the possible immunity that exists amongst injecting drug users that have recovered from HCV infection, and for understanding the role HCV testing interval has on measures of HCv re-infection in IDUs</gtr:partnerContribution><gtr:piContribution>WIthin this collaboration I have modelled:
1. The effect HCV testing interval has on experimental estimates of HCV re-infection and clearance. 
2. The role of combination interventions in preventing HIV transmission amongst injectors.
I will also be modelling the transmission of HCV amongst injecting drug users in Melbourne to understand the contribution of immunity to their epidemic.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manitoba</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Population and Public Health</gtr:department><gtr:description>Social, behavioral and transmission properties associated with diversity in HIV epidemics among people who inject drugs and other key populations</gtr:description><gtr:id>C2B8750A-D6E6-4272-8557-CE7A2067F063</gtr:id><gtr:impact>This collaboration has lead to funding from the Canadian Instutute of health research. The research is multi-disciplinary involving modelling and epidemicological research.</gtr:impact><gtr:outcomeId>HPoZTcA9pRr-1</gtr:outcomeId><gtr:partnerContribution>They have undertaken four rounds of bio-behavioural surveys amongst high-risk groups in different cities of Pakistan.</gtr:partnerContribution><gtr:piContribution>We are the lead mathematical modellers undertaking the modelling component of this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centers for Disease Control and Prevention (CDC)</gtr:collaboratingOrganisation><gtr:country>Georgia</gtr:country><gtr:department>Division of Viral Hepatitis</gtr:department><gtr:description>Modelling of HCV in US and Pakistan with US Centre for Disease Control</gtr:description><gtr:id>BBA9F2F8-A049-4704-8272-71F75D2140FE</gtr:id><gtr:impact>Presentation at EASL conference and CDC HCV conference</gtr:impact><gtr:outcomeId>56e67a4abf0f06.15307496-1</gtr:outcomeId><gtr:partnerContribution>We undertook modelling</gtr:partnerContribution><gtr:piContribution>We initiated new modeling to consider the transmission of HCV in USA and Pakistan, and impact of prevention and treatment intervention</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Social and Community Medicine</gtr:department><gtr:description>Collaboration with University of Bristol</gtr:description><gtr:id>839F06A6-D130-46E0-BC55-B30EABF61B2F</gtr:id><gtr:impact>19922515 20978062 20832198 20650522 20627977 21145810 21236265 21615585 21853030 21898506 and 

Vickerman, Peter (2011) The more you look the more you find - Effects of hepatitis C virus testing interval on re-infection incidence and clearance: Implications for future vaccine study design, Journal of Infectious Diseases In press 
 
Vickerman, Peter (2011) Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings - implications for intervention impact, Drug and Alcohol Dependence In press</gtr:impact><gtr:outcomeId>fMBKWL3bHbJ-1</gtr:outcomeId><gtr:partnerContribution>Provision of data for model analyses. Input into model analysis plans and co-authoring publications.</gtr:partnerContribution><gtr:piContribution>I have been involved in numerous projects with UOB where modelling has been involved. This has resulted in over 10 co-authored papers, the recruitment of a joint research assistant to undertake mathematical modelling of HCV in the UK, and a joint PhD student that is using network modelling to consider the transmission of HCV and HIV in different settings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Monitoring Centre for Drugs and Drug Addiction</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Collaboration with European monitoring centre for Drug Dependence and Addiction</gtr:description><gtr:id>64CCEA82-5679-4C51-9454-A1166F8607F7</gtr:id><gtr:impact>19922515 

Del Fava, Emanuele (2011) Joint Modeling of HCV and HIV Infections among Injecting Drug Users in Italy Using Repeated Cross-Sectional Prevalence Data, Statistical Communications in Infectious Diseases 3, 1
 
Vickerman, Peter (2011) Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings - implications for intervention impact, Drug and Alcohol Dependence In press</gtr:impact><gtr:outcomeId>86D8813E715-1</gtr:outcomeId><gtr:partnerContribution>They have provided HIV, HCV and HIV/HCV co-infection prevalence data from a wide range of European settings over many years</gtr:partnerContribution><gtr:piContribution>We undertook a systematic review of the relationship between HIV and HCV prevalence in injecting drug user populations from different settings. The data from EMCDDA made up a substantial part of that data set.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint United Nations Programme on HIV/AIDS (UNAIDS)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Impact of anti-retroviral treatment and harm reduction interventions on transmission of HIV amongst injecting drug users in Manipur, Northern India</gtr:description><gtr:id>8D9A68FC-C03D-43B0-A64D-B3A76211627E</gtr:id><gtr:impact>Funding from UNAIDS India and the Bill and Melinda Gates Foundation.</gtr:impact><gtr:outcomeId>WkVBnRXSoBF-1</gtr:outcomeId><gtr:partnerContribution>They are the go between between us and NACO of the Government of India, and are guiding the research to enable it to have maximum policy influence on Indian policy.</gtr:partnerContribution><gtr:piContribution>Undertaking mathematical modelling of the effect of anti-retroviral treatment and harm reduction interventions on the transmission of HIV and HCV amongst injecting drug users in two districts of Manipur, Northern India.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Kirby Institute</gtr:department><gtr:description>Collaboration with Kirby Institute, UNSW, Sydney, Australia</gtr:description><gtr:id>9342F369-E320-480B-9B2B-AC478FF2BC4F</gtr:id><gtr:impact>They are collaborators on a NIHR fellowship that was awarded to Natasha Martin in our group, we supervise a joint PhD student and we have a paper in press: 

Vickerman, Peter (2011) The more you look the more you find - Effects of hepatitis C virus testing interval on re-infection incidence and clearance: Implications for future vaccine study design, Journal of Infectious Diseases In press</gtr:impact><gtr:outcomeId>rCu13a747sx-1</gtr:outcomeId><gtr:partnerContribution>They have input into ongoing study ideas on using modelling to consider the impact of HCV treatment as prevention amongst IDUs. We have also worked on using modelling in connection with a large International pooled data set of cohort studies looking at HCV re-infection amongst IDUs. Further collaborations looking at the role that prison plays in promoting the transmission of HCV in different settings are underway.</gtr:partnerContribution><gtr:piContribution>I have contributed to their work in using modelling to analyse their data in ways that they were unable to do.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beth Israel Deaconess Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Baron Edmond de Rothschild Chemical Dependency Institute</gtr:department><gtr:description>Collaboration with Beth Israel Deaconess Medical Center, New York</gtr:description><gtr:id>CD8529AC-3A60-4443-80BB-FDB9A8FA171F</gtr:id><gtr:impact>We have submitted a paper considering the degree to which the HCV co-infection prevalence amongst HIV infected IDUs can be used to estimate the proportion of HIV infections that are sexually transmitted.</gtr:impact><gtr:outcomeId>rvFeTdCnvnf-1</gtr:outcomeId><gtr:partnerContribution>They have provided useful data on HIV and HCV prevalence from the epidemic amongst injecting drug users in New YorK. We have also submitted a paper considering whether HCV co-infection data can be used to estimate the porportion of HIV infections amongst injectors that are due to sexual transmission.</gtr:partnerContribution><gtr:piContribution>I am modelling the transmission of HCV and HIV amongst injecting drug users in New York. The model is being used to discern how existing interventions have reduced HIV in this setting and the degree to which HIV is transmissted sexually through considering the HCV and HSV-2 co-infection prevalence amongst HIV infected IDUs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Epidemiology and Biostatistics</gtr:department><gtr:description>International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts Collaborative Group update</gtr:description><gtr:id>09D8132B-A152-4246-92FC-735FDE409587</gtr:id><gtr:impact>Vickerman, Peter (2011) The more you look the more you find - Effects of hepatitis C virus testing interval on re-infection incidence and clearance: Implications for future vaccine study design, Journal of Infectious Diseases In press</gtr:impact><gtr:outcomeId>TCdwnTx3ijH-1</gtr:outcomeId><gtr:partnerContribution>Access to International pooled cohort data on re-infection amongst injectors</gtr:partnerContribution><gtr:piContribution>I use modelling to help understand some of the trends in their data such as studies with longer HCv testing intervals having lower re-infection clearance rates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Global Health Institute (GHI)</gtr:department><gtr:description>Modelling of HCV and HIV transmission dynamics in Tijuana, Mexico</gtr:description><gtr:id>FAC17CB7-BFE4-4370-A85F-91345A3ED224</gtr:id><gtr:impact>A paper is in press at Addiction.</gtr:impact><gtr:outcomeId>56e67aea728cd6.90401334-1</gtr:outcomeId><gtr:partnerContribution>We are undertaking modelling and joint PI of project</gtr:partnerContribution><gtr:piContribution>We are undertaking modelling of the HIV epidemic amongst different high risk groups in Tijuana</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Collaboration with Imperial College</gtr:description><gtr:id>83740FC2-4319-4874-BE20-20495FE81E0C</gtr:id><gtr:impact>No outputs at present linked to this award</gtr:impact><gtr:outcomeId>pzJ2TEHjFRk-1</gtr:outcomeId><gtr:partnerContribution>We have just started to supervise a joint PhD student that will be undertaking modelling amongst injection drug users in Myanmar</gtr:partnerContribution><gtr:piContribution>I will be supervising a modelling PhD</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hasselt</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Center for Statistics</gtr:department><gtr:description>Collaboration with University of Hasselt</gtr:description><gtr:id>32CFFDEC-7E2B-40AF-9D73-3216A5F585FE</gtr:id><gtr:impact>Del Fava, Emanuele (2011) Joint Modeling of HCV and HIV Infections among Injecting Drug Users in Italy Using Repeated Cross-Sectional Prevalence Data, Statistical Communications in Infectious Diseases 3, 1</gtr:impact><gtr:outcomeId>p3Rhwq3Sxua-1</gtr:outcomeId><gtr:partnerContribution>We are jointly supervising a PhD student that is using statistical methods and modelling to understand the joint dynamics of HIV and HCV in different settings</gtr:partnerContribution><gtr:piContribution>Expert advise on an analysis they did following on from my review of HIV and HCv data published in Addiction. Also helping supervise a PhD student who is modelling HIV and HCV amongst injectors.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Prevention of HCV transmission: Can it be done?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>633205BC-C0AC-46DB-A3B7-279D660DDEAB</gtr:id><gtr:impact>Invited talk to 70 health professionals in portsmouth on HCV prevention and modelling insights. There was considerable interest and good feedback from the talk.

None</gtr:impact><gtr:outcomeId>cMqTaNFSjH1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at '4th National Conference: Addiction and the Liver 2011.' London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>52AF1771-7053-4C26-8FA7-63CE1A89890E</gtr:id><gtr:impact>Presentation on 'Primary prevention of HCV'.

None as yet</gtr:impact><gtr:outcomeId>U9EkxpX4zpd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Two presentations at 'Simulation Models of Infectious Disease Transmission and Control Processes (SIMID) Workshop'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FC772A8E-3018-475C-A71D-F3AC6DCDE1AE</gtr:id><gtr:impact>Two talks on 'Modelling hepatitis C antiviral treatment for prevention amongst injecting drug users: impact and heterogeneity' and 'Can HCV co-infection prevalence amongst HIV infected injecting drug users be used as a marker of sexual HIV transmission?'. Lead to being asked to be involved as expert consultants on Belgian Health Care Knowledge Centre (KCE) project considering &amp;quot;Effectiveness and cost-effectiveness of hepatitis C screening and prevention programs.&amp;quot;

Report will be published on website: kce.fgov.be</gtr:impact><gtr:outcomeId>j3ftS5DcZ2x</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentaion at 'ECDC-EMCDDA Launch of guidance. Prevention and control of infectious diseases among people who inject drugs.'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9399B091-0487-4C87-B45B-3E1FA108BFA9</gtr:id><gtr:impact>Presentation on 'Primary prevention of HCV'. Influenced guidance document from EMCDDA/ECDC.

EMCDDA is initiating a group to discuss guidance for using HCV treatment as prevention</gtr:impact><gtr:outcomeId>RWbxdGhQNLY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation to 'Sussex Hepatology Network on using HCV treatment for prevention'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8350F39F-35DB-477E-BE9E-B378E20F353F</gtr:id><gtr:impact>Presentation on 'Hepatitis C prevention: modeling the impact and cost-effectiveness of antiviral therapy'. Presentation resulted in a discussion about improving treatment services in Sussex deanery.


None as yet</gtr:impact><gtr:outcomeId>ZSPCU5LPf5M</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at 'Annual Colloquium of Centre for Research Excellence into injecting drug use', Burnet Institute, Melbourne</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E32DCE3D-3F6A-4A02-AEE6-ED2981A2C3A8</gtr:id><gtr:impact>Presentation on 'Prevention of HCV transmission: Can it be done?' and 'Can antiviral therapy for HCV be a prevention tool for active IDUs? A modelling analysis'. Talk lead to indepth discussion of feasibility of using HCV antiviral treatment as a prevention strategy in Australia.

Had meeting with Health Minister for Victoria who was wanting to decide how to allocate a numbe rof new Hepatology nurses. Some of the nurses have been allocated to drug addiction centres</gtr:impact><gtr:outcomeId>QGQboaXSbGQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to 'Health Protection Scotland'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>98481E4D-66BD-4C11-A846-2250679D9D60</gtr:id><gtr:impact>Gave two talks on 'Can needle and syringe programmes and opiate substitution therapy achieve further reductions in HCV prevalence in a high coverage setting?' and 'Impact and cost-effectiveness of antiviral HCV treatment for prevention amongst IDUs'. Lead to extended discusssion about undertaking a trial to evaluate impact of HCV treatment for prevention amongst IDUs in Scotland and England.

We were granted further funding off HPS (&amp;pound;55,000) to undertake further modelling in this area, specifically aimed at considering specific sites that could be trial sites. Meeting with Jannsen is arranged for January 2012 to discuss their involvement.</gtr:impact><gtr:outcomeId>mi5YB4LgQ7r</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to 'Hepatitis C Action Plan Scotland Stakeholder Event, Glasgow'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DADA52EC-78F6-4D28-85F5-D28AADEC65B2</gtr:id><gtr:impact>Presentation on 'Can HCV treatment of active injecting drug users (IDUs) lead to a reduction in HCV transmission?'. Action plan has actively scaled up HCV treatment for injectors in Scotland and initial plans are underway to undertake a trial to consider the impact of HCV treatment for prevention in Dundee.


Initial discussions are underway with Jannsen about undertaking trial - 'HCV educational meeting' is being organized by Jannsen for 26 Jan 2012. We will be presenting on impact of HCV treatment for prevention.</gtr:impact><gtr:outcomeId>kGrDf2DtFjg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary presentation at 'HIV in European Region - Unity and Diversity' conference, Tallinn</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>913A24FF-3562-4FDD-8AAE-2756B64DF229</gtr:id><gtr:impact>Presentation on 'Impact of syringe exchange programmes and opiate substitution therapy to prevent HIV and HCV transmission among IDUs.'

None as yet</gtr:impact><gtr:outcomeId>kBnfi4HAW8z</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at 'Agence Nationale de Recherche sur le Sida et les hepatites virales (ANRS)' meeting. Paris</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>24E64262-46BF-488B-AB7D-473AC677959B</gtr:id><gtr:impact>Presentation on 'Modelling hepatitis C prevention: OST, NSP, and treatment'. Extensive discussion on HCV treatment for prevention. Plan is to apply for collaboration grant to undertake epidemiological study to explore impact of HCV treatment for prevention.

None as yet</gtr:impact><gtr:outcomeId>eNRpX1hTniw</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote speech to 'National Needle Exchange Forum Conference', Bristol</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9336F4BF-CC8A-4BA6-9D21-3D6ECBB4ECC9</gtr:id><gtr:impact>Presentation on 'Hepatitis C Prevention: Needle Exchange and Other Interventions'. Lead to discussion about improving treatment through addiction services.


None as yet</gtr:impact><gtr:outcomeId>af5Vz3PyHQG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary presentation at the 'National Conference on injecting drug use', Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A8FFA4CC-AD56-4E53-B2DD-47C76984E2CD</gtr:id><gtr:impact>Considerable debate on the use of HCV antiviral treatment for prevention.

None at present</gtr:impact><gtr:outcomeId>ma8fpJoqcFB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation to 'Hepatitis C and Liver Disease Prevention Event' in Bristol</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0E6DA781-F46D-4BBE-B951-FE7AF007A95B</gtr:id><gtr:impact>Invited presentation on 'Preventing hepatitis C - treatment'. Lead to lengthy discussion about improving access to HCV treatment in Bristol.



None as yet</gtr:impact><gtr:outcomeId>Ctsks1mVJtQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Two presentations at '2nd International Symposium on Hepatitis Care in Substance Users', Brussels</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DD02A28A-AB67-4B64-80C7-4F046B14B987</gtr:id><gtr:impact>Two presentations on 'Can HCV antiviral therapy be used for prevention? Modelling impact, cost-effectiveness, and heterogeneity.' and 'Can needle and syringe programmes and opiate substitution therapy achieve further reductions in HCV prevalence in a high coverage setting?'. Talks lead to discussion session on feasibility of HCv treatment for prevention.

None as yet</gtr:impact><gtr:outcomeId>gLQBpaTFuY1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>College on Problems of Drug Dependence 2011 Symposium (Miami) - Frontiers in systems modelling: bridging science and policy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C4A9A32-8620-43A1-8B76-36D037A53D94</gtr:id><gtr:impact>Presentation on 'Primary prevention of hepatitis C in injecting drug users and population: modelling the impact and role of opiate substitution treatment, needle exchange and HCV antiviral treatment'

None as yet</gtr:impact><gtr:outcomeId>Btwdw2e1ZK4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at 'Welsh Action Plan Treatment and Care Subgroup'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A6B6C31-9326-4B47-AE2C-504022D4ACA3</gtr:id><gtr:impact>Presentation on 'Can antiviral therapy for HCV reduce prevalence among active IDUs? A modeling analysis'. Marion Lyons (Consultant in Communicable Disease Control) urged the representatives from each deanery in Wales to increase testing and treatment of IDUs.


A number of hepatology nurses have been employed and increased emphasis is being placed on treating IDUs.</gtr:impact><gtr:outcomeId>mC2ZPJ9JMQQ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to 'Belgium Institute for Tropical Medicine Episeminary'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7C48EA1-1DB4-4D55-94BD-EABA1224A3ED</gtr:id><gtr:impact>Presentation on 'The impact and cost-effectiveness of hepatitis C antiviral treatment for prevention among injecting drug users.' Lead to us being involved in their National guidance on the strategies to prevent HCV transmission. 


None as yet</gtr:impact><gtr:outcomeId>hG48dZy6YWr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at 'Hepatitis C, Substance Misuse and Health Inequalities: Delivering a Consensus for London'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E41BA0F7-4484-45FA-AEA2-B5782A690C57</gtr:id><gtr:impact>Gave a talk on 'The Utility of Antiviral Treatment for Primary Prevention of Hepatitis C'. Resulted in the development a consensus statement outlining a cohesive plan for better hepatitis C treatment and care pathways in London for injecting drug users-- this document included a section on hepatitis C treatment as prevention and includes a figure from our slides. The consensus statement was presented to public health commissioners.


none as yet</gtr:impact><gtr:outcomeId>aLSckEPDK39</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentations at 'European Monitoring Centre for Drugs and Drug Addiction'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3D6AE3FC-65A5-4C6A-8542-2DD9C615240A</gtr:id><gtr:impact>Invited presentations on 1. 'HCV antiviral treatment as prevention' and 2. 'Can HCV co-infection prevalence amongst HIV infected IDUs be used as a marker of sexual HIV transmission?' 3. 'Initial model analyses of the joint epidemiology of HCV and HIV amongst injecting drug users '. As a result, presentation was given to EU and sparked extended debate.

EMCDDA has initiated a working group considering HCV treatment as prevention. Meeting due to be held in Lisbon in April 2012.</gtr:impact><gtr:outcomeId>dkH4fsB259S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant for undertaking modelling to guide Scottish HCV action plan</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Government of Scotland</gtr:fundingOrg><gtr:id>18EE6C74-1924-4E2D-A500-B165B575C590</gtr:id><gtr:outcomeId>N4qvhbkUu6f0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH NIDA R01 call</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>R01 DA037773-01A1</gtr:fundingRef><gtr:id>035C5A22-8133-4892-9569-57638E4E9214</gtr:id><gtr:outcomeId>56e67b94207321.33563130</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3899936</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicine to Optimise the Treatment of Patients with Hepatitis C Virus Infection (STOP HCV)</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K01532X/1</gtr:fundingRef><gtr:id>77F5DAED-6351-45A3-94F8-D1A991791DF4</gtr:id><gtr:outcomeId>qwpoS9DdETW</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Technical Proposal for &amp;quot;Estimating cost-effectiveness for screening strategies for HBV, HCV and HIV infections in different populations in Europe&amp;quot;</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>65C391A8-F2DA-4F78-B84B-1B382DD567C7</gtr:id><gtr:outcomeId>dyA7LDaxRqU0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Development grant on 'Can HCV treatment be delivered to injecting drug users in order to reduce HCV transmission and prevalence in the population: an empirical demonstration and evaluation'</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8B3EB6DA-72E1-493C-BC0F-9BD59B1C4498</gtr:id><gtr:outcomeId>Ag5LUHMsjt50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Impact of ART on HIV transmission amongst IDUs and FSWs in India</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Joint United Nations Programme on HIV/AIDS (UNAIDS)</gtr:fundingOrg><gtr:id>9891BCE5-BFA3-4B71-9130-EFBCBC05CD9B</gtr:id><gtr:outcomeId>J9TgCaAKmP1</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26110</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cost-effectiveness of expanding ART provision to HBV co-infected individuals</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>3352A03C-B806-4A3C-A454-16EEB1B53428</gtr:id><gtr:outcomeId>LpXFb1xo4fe</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11000</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Effectiveness and cost-effectiveness of hepatitis C screening and prevention programs</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Belgian Health Care Knowledge Centre (KCE)</gtr:fundingOrg><gtr:id>58977B52-2F4B-46CF-9B91-385B2F6C77F7</gtr:id><gtr:outcomeId>HT3mxYAUkXy0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant for undertaking modelling to guide Scottish HCV action plan</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Government of Scotland</gtr:fundingOrg><gtr:id>CB949CFD-D5CF-444B-B4AE-83306DBB59BF</gtr:id><gtr:outcomeId>tP6p86TZDQD0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125420</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Economic Analysis to inform the development of NICE public health intervention guidance on 'Hepatitis B and C: ways to promote and offer testing to people at risk of infection'</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>National Institute for Health and Care Excellence (NICE)</gtr:fundingOrg><gtr:id>8E41B434-6294-4B04-B41A-E39CB6AB26B8</gtr:id><gtr:outcomeId>codmkMBfD810</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10300</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cost-effectiveness of expanding ART provision to HCV co-infected indiviuals</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>E60A086F-0374-46C6-A201-A9B50147F808</gtr:id><gtr:outcomeId>MQfEsviNrSm</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27184</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Literature review of HCV and HBV co-infection globally</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>9D2A3632-B285-4ED1-8314-25974C5868F1</gtr:id><gtr:outcomeId>efkFMEz65kE</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Postdoctoral Fellowship on 'Interventions to reduce hepatitis C virus transmission among injecting drug users'</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>C137DC9E-722A-4212-B0A5-ECE21F9BA3B0</gtr:id><gtr:outcomeId>mUZN5qpsE9b0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>282000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Assessing the impact and cost-effectiveness of needle/syringe provision on hepatitis C transmission among people who inject drugs: an analysis of pooled datasets and economic modelling</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/3070/13</gtr:fundingRef><gtr:id>27946E36-7ADF-47A0-A2C4-CEC833BF093F</gtr:id><gtr:outcomeId>AU6zQuUTdgy</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>435000</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>CAD</gtr:currCode><gtr:currCountryCode>Canada</gtr:currCountryCode><gtr:currLang>en_CA</gtr:currLang><gtr:description>Social, behavioral and transmission properties associated with diversity in HIV epidemics among people who inject drugs and other key populations</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Canadian Institutes of Health Research</gtr:fundingOrg><gtr:fundingRef>275499</gtr:fundingRef><gtr:id>457513FA-0F60-4BDB-8682-0B6BD2F2E1B0</gtr:id><gtr:outcomeId>ZpckrvAHP9S</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21189</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cost-effectiveness of expanding ART provision to injecting drug users and men who have sex with men In India</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>771311BB-FA2C-4E96-9117-29E590DE712D</gtr:id><gtr:outcomeId>JVdLqctsdrN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HCV treatment as prevention working group for European Monitoring Centre for Drugs and Drug Addiction</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>6525436A-46BD-49F6-A28B-1B817D2DE1DD</gtr:id><gtr:outcomeId>tmVzBUZvVzx</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO guidance for improving surveillance and prevention of HCV and HBV amongst injectors</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>258F9888-D73B-44DD-AA91-3CD85960D864</gtr:id><gtr:outcomeId>G2GVoKDZ8jM</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Undertaking economic analyses for NICE gidelines on how to increase testing for HCV and HBV</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DFB27BB1-11C5-42F6-B87F-A3C42B23BA01</gtr:id><gtr:outcomeId>a2ELXgzwqRz</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input into Belgium guidelines for preventing hepatitis C virus (HCV) amongst injectors</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>9D70652A-4A57-4ED8-91CD-708BEA9F39D5</gtr:id><gtr:outcomeId>Ns7BC7GJ3gU</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ECDC-EMCDDA guidance report</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>ECDC-EMCDDA guidance report Prevention and control of infectious diseases among people who inject drugs</gtr:guidelineTitle><gtr:id>EF8F7219-C618-4DF0-A31F-A123ADBE0FEA</gtr:id><gtr:outcomeId>WAp3kFCUZ6Z</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.emcdda.europa.eu/publications/ecdc-emcdda-guidance</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Modelling to feed into WHO guidance on prioritisation of anti-retroviral treatment for injecting drug users and HCV or HBV and HIV co-infected individuals</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FCE8C75E-131D-458E-AF23-0FEAC0CCBE28</gtr:id><gtr:outcomeId>pEtFi1tWkkt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influenced Scottish and Welsh policy makers in use of HCV antiviral treatment as prevention</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>107AB895-A62D-4A47-99B4-DD257E769026</gtr:id><gtr:outcomeId>FES83qSmEVS</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Through modelling we evaluated the use of an existing treatment (antiviral treatment for HCV infection) that can cure HCV infection for reducing the transmission of HCV amongst injecting drug users. The impact and cost-effectiveness results have been published in Journal of Hepatology and Hepatology. Since then we have been successful in obtaining further funding from NIHR (research fellowship for further modelling and program development grant for undertaking field studies) and Helath protection Scotland to progress this concept further. Additional interest has also been shown from Jannssen for undertaking a study in a number of Uk settings</gtr:description><gtr:id>927AEF4D-904A-4541-A078-B21193B1E2B5</gtr:id><gtr:impact>The results of the analysis has lead the HCV action plan for Wales and Scotland to actively include HCV treatment of injecting drug users in their strategies and both plan to evaluate its effect. It has also been included in the guidaance for Balgium government and from ECDC.</gtr:impact><gtr:outcomeId>nMBUhyh8BJk</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HCV antiviral treatment for prevention of HCV transmission amongst injecting drug users</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A number of bio-behavioural survey data sets were pooled from different settings in the UK to undertake an analysis on the risk factors for recent HCV infection amongst injecting drug users</gtr:description><gtr:id>F5B3FFDA-1C5B-4FBD-A55B-6341B6352BCC</gtr:id><gtr:impact>Analysis showed that opiate substitution therapy and high coverage needle and syringe distribution are associated with considerable decreases in HCV transmission risk. Paper was published in Addiction and has lead to a modelling analysis to consider the impact of scaling up these interventions on HCV prevalence

21615585 Turner Katy M E (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence., Addiction (Abingdon, England) 106, 11, 1978-88</gtr:impact><gtr:outcomeId>N9aSxpdZ2mt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>UK pooled HCV survey data for injecting drug users</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new model of HIV and HCV transmission amongst injecting drug users was developed. The model tracks the co-infection status of HIV and HCV and has enabled us to explore the interactions between these infections in a detailed way.</gtr:description><gtr:id>A421B410-0A2A-4C06-AA62-4DA49AA681E1</gtr:id><gtr:impact>Analyses are ongoing to explore the possible determinants for the different observed HIV and HCV epidemics that occur in different settings. This analysis is in press at DAD: 

Vickerman, Peter (00, 2011) Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings - implications for intervention impact, Drug and Alcohol Dependence In press, , Edit</gtr:impact><gtr:outcomeId>6463D97F770</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mathematical model of HIV and HCV transmission</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The model is in excel and estimates the increase in quality of life (QALYs) from providing antiviral treatment to active of ex- injecting drug users. The model suggests it is a highly cost-effective strategy.</gtr:description><gtr:id>BFB26813-FBE7-42F1-8F91-0D37D3616CF3</gtr:id><gtr:impact>Paper has been published and has been of much interest to people interested in HCV prevention amongst injecting drug users:

21898506 Martin Natasha K (2011) The cost-effectiveness of HCV antiviral treatment for injecting drug user populations., Hepatology (Baltimore, Md.)</gtr:impact><gtr:outcomeId>rAQnoyYLeYk</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Economic model of impact of antiviral treatment on HCV transmission</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A model was developed to explore if antiviral treatment for HCV could be used to substantially reduce the prevalence and transmission of HCV.</gtr:description><gtr:id>EA628A4D-0BE4-4C4C-B29C-A16625E3F81B</gtr:id><gtr:impact>20832198 Vickerman Peter (2011) Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere., Drug and alcohol dependence 113, 2-3, 83-5; discussion 86-7

21145810 Martin Natasha K (2011) Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility., Journal of hepatology 54, 6, 1137-44 

21236265 Martin Natasha K (2011) Mathematical modelling of hepatitis C treatment for injecting drug users., Journal of theoretical biology 274, 1, 58-66 
 
21853030 Martin Natasha K (2011) Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users., PloS one 6, 8
 
21898506 Martin Natasha K (2011) The cost-effectiveness of HCV antiviral treatment for injecting drug user populations., Hepatology (Baltimore, Md.) 

The results have had substantial interest from policy makers in UK and Australia</gtr:impact><gtr:outcomeId>kpF58YMD6zb</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mathematical model of effect of antiviral treatment on HCV transmission</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20832200</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The model has been used to understand how the sexual and injecting transmission of HIV in injecting drug users effects the prevalence of HCV amongst HIV infecteds. The model translates the HCV co-infection prevalence into an estimate for the proportion of HIV infections due to injecting.</gtr:description><gtr:id>4687DC0B-4782-4DEC-8E9A-A79FC0FAD90A</gtr:id><gtr:impact>Work gained considerable interest when presented to EMCDDA and elsewhere. Paper submitted to AIDS: 

Vickerman, P. et al. Is the HCV/HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related transmission of HIV?</gtr:impact><gtr:outcomeId>XDonr4AGPAx</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mathematical model of HCV co-infection in HIV infecteds</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>785284B8-893C-408F-B318-6B8D683A8AAE</gtr:id><gtr:title>The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7118a725df21e9e0c12e4d9a8580ec7"><gtr:id>c7118a725df21e9e0c12e4d9a8580ec7</gtr:id><gtr:otherNames>Guinness L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>f2coFoeyeoT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EAE0EE8-6844-4D81-98B2-C3E1A4E1D98C</gtr:id><gtr:title>Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>pm_540e15ae15a2efe3f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0F7771A-63A2-4490-8362-49E9DAAF1113</gtr:id><gtr:title>Mathematical modelling of hepatitis C treatment for injecting drug users.</gtr:title><gtr:parentPublicationTitle>Journal of theoretical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-5193</gtr:issn><gtr:outcomeId>bJdzTGTbGw8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76FA08CF-A7CF-451B-8398-701E08A63256</gtr:id><gtr:title>Joint Modeling of HCV and HIV Infections among Injecting Drug Users in Italy Using Repeated Cross-Sectional Prevalence Data</gtr:title><gtr:parentPublicationTitle>Statistical Communications in Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88b0c03f3036878ced9dccfe9c297cd6"><gtr:id>88b0c03f3036878ced9dccfe9c297cd6</gtr:id><gtr:otherNames>Del Fava E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>i5AdEp7YWkH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44348460-481D-49FE-B795-583F607A3925</gtr:id><gtr:title>Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd3a6d4133940d4cf95819a7bcc108d"><gtr:id>dfd3a6d4133940d4cf95819a7bcc108d</gtr:id><gtr:otherNames>MacArthur GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_15862_22_23038795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4F5B661-18AB-41BF-B454-7D373024F050</gtr:id><gtr:title>The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a54e8586de7b72fc147f08ac5891f9cc"><gtr:id>a54e8586de7b72fc147f08ac5891f9cc</gtr:id><gtr:otherNames>Scott N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56e6793e431415.60244550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91F2463D-B75B-4B82-88EA-C1E586635504</gtr:id><gtr:title>A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective.</gtr:title><gtr:parentPublicationTitle>Epidemics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4d2982799bda171a10ebfb432581b01"><gtr:id>b4d2982799bda171a10ebfb432581b01</gtr:id><gtr:otherNames>Castro Sanchez AY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-0067</gtr:issn><gtr:outcomeId>pm_15862_22_23438431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD20617-39E7-4427-853E-5590B08E1CCE</gtr:id><gtr:title>HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bc871398210973dae1e015c24cf751f"><gtr:id>1bc871398210973dae1e015c24cf751f</gtr:id><gtr:otherNames>Delva W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_15862_22_22802738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>891DF26E-6999-4239-97D6-AFF067D99880</gtr:id><gtr:title>Policy resistance to harm reduction for drug users and potential effect of change.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/154c821ffe457f8f71813b15f2d2ff04"><gtr:id>154c821ffe457f8f71813b15f2d2ff04</gtr:id><gtr:otherNames>Rhodes T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>JGSz6wGopDm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F6C94EF-54B8-4C5E-A98D-4DA6D611D65F</gtr:id><gtr:title>Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5683d528d5840ee74c0f63b7fed1b7c"><gtr:id>d5683d528d5840ee74c0f63b7fed1b7c</gtr:id><gtr:otherNames>Platt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56e6793d2d8077.75117182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F0B0123-5894-4B5D-91CA-5CC8C70BB93D</gtr:id><gtr:title>Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e6f663b28855b579541186a7750df38"><gtr:id>6e6f663b28855b579541186a7750df38</gtr:id><gtr:otherNames>Cornish R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>NFnHNUSiU2Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38646EE1-F174-49DF-BD17-EEC1E7E31B21</gtr:id><gtr:title>Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>B0EE69D6F92</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>987738BA-557A-4292-94E8-99ED36FD2B39</gtr:id><gtr:title>Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/154c821ffe457f8f71813b15f2d2ff04"><gtr:id>154c821ffe457f8f71813b15f2d2ff04</gtr:id><gtr:otherNames>Rhodes T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56e6793ea26dc6.46286284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F3DD18D-76D5-4C30-A4F4-322EC95CA9A2</gtr:id><gtr:title>Influence of different drugs on HIV risk in people who inject: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/497aa845f3c24e06291272d0a9f41272"><gtr:id>497aa845f3c24e06291272d0a9f41272</gtr:id><gtr:otherNames>Tavitian-Exley I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>56e6793ec7c541.25445200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF3183FA-1825-4563-9839-A82300A6D559</gtr:id><gtr:title>Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>pm_15862_22_22564041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6031D90B-FE4B-459D-A886-2C801CC20B31</gtr:id><gtr:title>Commentary on Mehta et al. (2012): Natural history of injecting drug use.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a21002105f03f66eed67137e868864"><gtr:id>b6a21002105f03f66eed67137e868864</gtr:id><gtr:otherNames>Hickman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>pm_15862_22_22248140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C42DF66-CF07-4E8D-A6BF-08D6DFC02C9D</gtr:id><gtr:title>Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56e6793d8f4f09.87352054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A731BBB6-3C62-4F1E-ADFE-3B8DCFD010E4</gtr:id><gtr:title>Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>inQJxawa5nE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4682FDD1-B17D-43BD-A053-C8BE2735FF05</gtr:id><gtr:title>Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e58926b7b60434f70ad8cc2b0a77c5"><gtr:id>b4e58926b7b60434f70ad8cc2b0a77c5</gtr:id><gtr:otherNames>Degenhardt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>twFcNnaR36x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EF99172-FCB1-4D9A-BBA6-922E93BD8C11</gtr:id><gtr:title>Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bea35a40a8c3fecfe308ef4002c8e88"><gtr:id>3bea35a40a8c3fecfe308ef4002c8e88</gtr:id><gtr:otherNames>Miners AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>pm_15862_22_24215210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72D3BFD5-A13F-4C13-A15F-8076113CFFB1</gtr:id><gtr:title>Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6653b624be9ed5899836779414b38032"><gtr:id>6653b624be9ed5899836779414b38032</gtr:id><gtr:otherNames>Mumtaz GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56e6793e13e924.97608372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ED6A5FC-7A09-4CDA-872D-90C7FA25C9F0</gtr:id><gtr:title>Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_15862_22_23943776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFCB96D3-B491-4E2C-87F6-F60C45D133F1</gtr:id><gtr:title>HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f06943c41207ca4a6d69506d5b28732"><gtr:id>8f06943c41207ca4a6d69506d5b28732</gtr:id><gtr:otherNames>Fraser H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58c223054bd013.44402532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F150D36-7F37-4123-BD23-69B65C1F987C</gtr:id><gtr:title>The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_15862_22_22457292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7005B44E-8260-40F1-B607-E4B2F5F0AADD</gtr:id><gtr:title>How cost-effective is hepatitis C virus treatment for people who inject drugs?</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology and hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0815-9319</gtr:issn><gtr:outcomeId>pm_15862_22_23527756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>635D8688-0422-4D53-9430-D8B5BA37A8D6</gtr:id><gtr:title>Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a21002105f03f66eed67137e868864"><gtr:id>b6a21002105f03f66eed67137e868864</gtr:id><gtr:otherNames>Hickman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>56e6793ddfccc7.04270172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>617DD15B-0A09-4DCD-A818-35BEA048E384</gtr:id><gtr:title>Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.</gtr:title><gtr:parentPublicationTitle>The Medical journal of Australia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a04bd5ce557b34fa4b36fb8d74adc7d"><gtr:id>8a04bd5ce557b34fa4b36fb8d74adc7d</gtr:id><gtr:otherNames>Hellard ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0025-729X</gtr:issn><gtr:outcomeId>pm_15862_22_22676879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4681610F-BC49-42B4-9B20-3844C9A69E36</gtr:id><gtr:title>Commentary on de Vos et al. (2013): can ecological trends in HIV or HCV incidence be used to assess intervention impact?</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>pm_15862_22_23659844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DBA3D79-4D43-41D7-9A58-7951F2E66530</gtr:id><gtr:title>Could low dead-space syringes really reduce HIV transmission to low levels?</gtr:title><gtr:parentPublicationTitle>The International journal on drug policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0955-3959</gtr:issn><gtr:outcomeId>pm_15862_22_23206493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF05CA06-0CEC-4154-B89A-3CDEFC4036FC</gtr:id><gtr:title>Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>sPjrTHMZ8mf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1C71290-14A7-4680-882E-394A181E2000</gtr:id><gtr:title>Promoting recovery and preventing drug-related mortality: competing risks?</gtr:title><gtr:parentPublicationTitle>Journal of public health (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a21002105f03f66eed67137e868864"><gtr:id>b6a21002105f03f66eed67137e868864</gtr:id><gtr:otherNames>Hickman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1741-3842</gtr:issn><gtr:outcomeId>pm_15862_22_21788295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0D51C94-CDBC-4DD3-8208-F5030B96AA68</gtr:id><gtr:title>The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6564d4c2d448be42a8c41421b455e277"><gtr:id>6564d4c2d448be42a8c41421b455e277</gtr:id><gtr:otherNames>Turner KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>BbZqeyYXL8k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC5B7EBC-90D4-49F6-9107-0EB4B73032CD</gtr:id><gtr:title>HIV transmission from drug injectors to partners who do not inject, and beyond: modelling the potential for a generalized heterosexual epidemic in St. Petersburg, Russia.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/531e490605bdca10c1b955f966b3cfd1"><gtr:id>531e490605bdca10c1b955f966b3cfd1</gtr:id><gtr:otherNames>Mills HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>pm_15862_22_23692991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35C2AC39-52A1-4F39-A547-9583D56ED1D7</gtr:id><gtr:title>Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/531e490605bdca10c1b955f966b3cfd1"><gtr:id>531e490605bdca10c1b955f966b3cfd1</gtr:id><gtr:otherNames>Mills HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>pm_15862_22_22728045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>316F8769-51D2-470D-B6DE-BC587640A4C6</gtr:id><gtr:title>Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>pm_15862_22_22138540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654C7310-6A1B-4589-8005-6C6E9A4DA2FB</gtr:id><gtr:title>Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e5c182f94700ef095152ec11aad462e"><gtr:id>7e5c182f94700ef095152ec11aad462e</gtr:id><gtr:otherNames>Sacks-Davis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>doi_55faa1aa1db068d4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33F66266-BF5E-4B47-8B12-E2073650525B</gtr:id><gtr:title>Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_15862_22_23884064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4713EA17-A8E3-460A-BD06-7313D42A5498</gtr:id><gtr:title>Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling.</gtr:title><gtr:parentPublicationTitle>The International journal on drug policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0955-3959</gtr:issn><gtr:outcomeId>5675dd3d86b88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06D9C85A-B259-4CD1-82EE-E40FFEBF712F</gtr:id><gtr:title>Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15862_22_23553643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E645BB4-8296-4ED2-8163-06E3CD797454</gtr:id><gtr:title>Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>qEYnQbiFjwu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1BC628A-40EA-4081-91B5-3D6586B52F9D</gtr:id><gtr:title>Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56e6793db98666.12276446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13E6EF88-3078-4C65-BD10-90209F9324ED</gtr:id><gtr:title>Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19ee875b357966f4796d3886615aaf51"><gtr:id>19ee875b357966f4796d3886615aaf51</gtr:id><gtr:otherNames>Martin TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15862_22_23736152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8838F9F-3B6E-4554-B32B-6C3121C279C3</gtr:id><gtr:title>Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>VjhYNjWNRyH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2273FA39-DA7D-43F6-95BF-460595888500</gtr:id><gtr:title>Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56e6793d6de426.67998555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEB4D023-7300-4B67-ADF6-FF6BE17E581D</gtr:id><gtr:title>Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>AA8FE34BEAA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAFB75A7-BE91-48E3-992F-F2952A85EF2E</gtr:id><gtr:title>The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56e6793e7e38d9.03940294</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701627</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>